Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This is an open label study to prospectively evaluate the effect of adjunct use of
Aripiprazole, as an agent to improve metabolic profile and induce weight loss in patients
established on atypical antipsychotics (Olanzapine, Clozapine and Risperidone).